Page 610«..1020..609610611612..620630..»

Umbilical Cord Blood Banking Market Size to Expand Significantly by the End of 2025 – BioSpace

Posted: October 28, 2021 at 2:48 am

Umbilical cord blood or cord blood refers to the blood that stays inside the placenta and umbilical cord after delivery. Toward the end of term, maternal-fetal cell transfer takes place to better the immune system of both baby and mother, thereby preparing both for labor. Umbilical cord blood becomes a very rich source of stem cells. It also contains cells of the immune system. Umbilical cord blood refers to the process of collection of this cord blood, which is then extracted from the source and cryogenically frozen in its stem cells or other immune system cells. It is then stored for potential use for medical purposes in future.

Cord Blood America, Inc, Cryo-Cell International, Inc, Cordlife Group Limited, Cord Blood Registry Systems, Vita 34 International, and StemCyte Inc are few renowned companies in the globalumbilical cord blood banking market.

Transparency Market Research (TMR) has prepared a comprehensive study on the global umbilical cord blood banking market, for the period 2017 to 2025. The market is prophesized to rise at a promising growth rate of 11.4% CAGR during the period of review.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=19922

Rise in the Awareness to Fuel Growth of the Market in Asia Pacific

Considering geography, North America is likely to take lead in the global umbilical cord blood banking market. The regional dominance of North America in the market is attributed to increasing demand for umbilical cord blood for stem cell research. There are other factors as well that favor the growth of the market in years to come. Augmented investment by the various pharmaceutical companies coupled with improvement in the research and development infrastructure is likely to boost the global umbilical cord blood banking market.

The Asia Pacific region is likely to emerge as a rapidly growing region in the global umbilical cord blood banking market. With the presence of a huge untapped market in Asia Pacific and immense potential for growth is estimated offer fuel growth of the regional market. In addition, augmented awareness about the benefits of umbilical cord banking in the region, particularly in China and India, is forecasted support rise of the global umbilical cord blood banking market toward prominence.

TOC of Report - https://www.transparencymarketresearch.com/report-toc/19922

Rapid Technological Advancement Favor Growth of the Market in Forthcoming Years

The global umbilical cord blood banking market is likely to gather momentum mainly from the increasing awareness about its benefits across the globe. Blood forming stem cells find ample use in the treatment of several blood-related disorders. Apart from that, there is immense scope for the application of umbilical cord blood in the treatment of disorders that require cell-based therapies. Such preference for umbilical cord blood is owing to its capability of harvesting hematopoietic stem cells. Later on, these cells find use as an instant medical solution for many malignant as well as non-malignant blood diseases. Certain types of cancer, leukemia, few metabolic disorders, and sickle-cell anemia are some of the diseases that could be cured utilizing umbilical cord blood.

Buy Umbilical Cord Blood Banking Market Report at - https://www.transparencymarketresearch.com/checkout.php?rep_id=19922&ltype=S

The information shared in this review is based on a TMR report, bearing the title, Umbilical Cord Blood Banking market (Storage - Public Cord Blood Banks and Private Cord Blood Banks; Application - Cancers, Blood Disorders, Metabolic Disorders, Immune Disorders, and Osteoporosis; End User - Hospitals, Pharmaceutical Research, and Research Institutes) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2017 to 2025

More Trending Reports by Transparency Market Research:

Radiopharmaceuticals Market: Over the past few decades, immunology, biology, and genetics have progressed at a considerable pace due to which the development of cardiological, oncological, and neurological therapies has received a much-needed push. In the past 20 years, multiple radionuclide-based targeted therapies have gradually emerged as one of the most efficient techniques for inflammatory lesions and cancer treatment.

Roadside Drug Testing Devices Market: An alarming rate of deaths caused due to drink and drive scenarios are increasingly becoming a matter of concern for government authorities worldwide. Thus, innovations in the healthcare industry are generating incremental opportunities for companies in the roadside drug testing devices market. For instance, inDecember 2019,Abbott-a global leader in medical devices announced the launch of the SoToxa Mobile Test System, which is acquiring global recognition. Novel roadside drug testing devices are gaining importance to combat drug-impaired driving and ensure road safety.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact

Mr. Rohit BhiseyTransparency Market Research

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com/

Read the rest here:
Umbilical Cord Blood Banking Market Size to Expand Significantly by the End of 2025 - BioSpace

Posted in Stem Cells | Comments Off on Umbilical Cord Blood Banking Market Size to Expand Significantly by the End of 2025 – BioSpace

European Wellness Collaborates with Heidelberg University Germany to Conduct Efficacy Studies of Peptides and Cell Therapy Research -…

Posted: October 28, 2021 at 2:48 am

Published: Oct. 27, 2021 at 4:30 AM EDT|Updated: 22 hours ago

FRANKFURT, Germany, Oct. 27, 2021 /PRNewswire/ European Wellness Academy (EWA), the educational arm of European Wellness Biomedical Group (EWG), has signed an agreement to carry out joint scientific research on the efficacy of peptides, cell therapy, exosomes and cell reprogramming for rejuvenation in premature murine aging models.

EWA was represented by its Group Chairman, Prof. Dr. Mike Chan, while Heidelberg University was represented by its Commercial Managing Director, Katrin Erk and its Head of Institute of Anatomy and Cell Biology III, Prof. Dr. Thomas Skutella.

The cutting-edge therapeutics used for the studies include precursor (progenitor) stem cells (PSC), precursor cells (Frozen Organo Crygenics (FOC)), Mito Organelle (MO), Nano Organo Peptides (NOP) and exosomes.

Their studies include in vitro experiments concentrating on the effects of the products on the aging of somatic cells and cellular senescence, which is known to contribute to disease onset and progression. Investigated exosomes include neuronal stem cells (NSCs), mesenchymal stem cells (MSCs), cardiomyocytes, kidney progenitors and hepatocytes.

EWA and Heidelberg University will also conduct in vivo experiments to demonstrate both safety and efficacy of the therapeutics, whereby the proof of effectivity will be recorded in the life span, histopathological and molecular criteria of neurodegeneration including Alzheimer/dementia, and system degeneration disorders including those affecting the immune system, skin, cardio, lung, kidney, liver, stomach/intestine/gut, eye, and muscular dystrophy.

Other criteria included are cartilage/joint/bone regeneration including knees/joints/hips, cervical, thoracic, lumbar, pelvic and musculoskeletal disorder, as well as endocrine disorders like endocrinal dysfunction due to over and underproduction of hormones and other activity pattern under the sleep wake cycle.

The ongoing specially designed studies are coordinated and designed by Prof. Dr. Thomas Skutella of Heidelberg University, a world-renowned research university and one of Germany's Top 3, Prof. Dr.Mike Chan and scientists of EWG.

European Wellness Academy

Located in Germany, Switzerland, Greece and Malaysia, EWA is a UK CPD authorised body with a premium training and development wing that revolves around cutting-edge Bio-Regenerative Medicine modalities for practitioners and researchers. The Academy has extensive years of combined clinical experience and a core academic team comprising of qualified clinicians and scientists with multiple international affiliations and accreditations.

https://ewacademy.euhttps://european-wellness.eu/

View original content to download multimedia:

SOURCE European Wellness Biomedical Group

The above press release was provided courtesy of PRNewswire. The views, opinions and statements in the press release are not endorsed by Gray Media Group nor do they necessarily state or reflect those of Gray Media Group, Inc.

See the original post:
European Wellness Collaborates with Heidelberg University Germany to Conduct Efficacy Studies of Peptides and Cell Therapy Research -...

Posted in Stem Cells | Comments Off on European Wellness Collaborates with Heidelberg University Germany to Conduct Efficacy Studies of Peptides and Cell Therapy Research -…

Biohaven Enrolls Phase 1a/1b Clinical Trial of BHV-1100, Lead Asset from its ARM (Antibody Recruiting Molecule) Platform, in Combination with NK Cell…

Posted: October 28, 2021 at 2:48 am

-- Biohaven initiates a clinical trial of the novel antibody recruiting molecule BHV-1100 to assess safety, tolerability, and exploratory clinical activity in Multiple Myeloma

Published: Oct. 27, 2021 at 5:30 AM MDT|Updated: 19 hours ago

NEW HAVEN, Conn., Oct. 27, 2021 /PRNewswire/ --Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), announced the enrollment of the first patient in a Phase 1a/1b trial in Multiple Myeloma using the ARM, BHV-1100, in combination with autologous cytokine induced memory-like (CIML) natural killer (NK) cells and immunoglobulin (Ig) to target and kill multiple myeloma cells expressing the cell surface protein CD38 (Figure 1). BHV-1100 is the lead clinical asset from Biohaven's ARM Platform, developed from a strategic alliance with PeptiDream Inc. This clinical trial will assess the safety and tolerability, as well as exploratory efficacy endpoints, in newly diagnosed multiple myeloma patients who have tested positive for minimal residual disease (MRD+) in first remission prior to autologous stem cell transplant (ASCT).

NK cells are part of the innate immune system, which is designed to recognize and destroy "non-self" or diseased cells in the body. However, tumor cells can evade detection by immune effector cells, allowing the tumor to advance. BHV-1100 targets a cell-surface protein, CD38, that is heavily overexpressed on multiple myeloma and binds to it, recruiting primed autologous cytokine induced memory-like (CIML) natural killer (NK) cells to destroy the tumor.

Charlie Conway, Ph.D., Chief Scientific Officer at Biohaven commented, "While many recent advances have been made to benefit multiple myeloma patients, most patients will unfortunately still relapse. We are excited to investigate BHV-1100 for its ability to recruit autologous CIML NK cells to the site of the tumor. Based on preclinical data from Biohaven Labs, we anticipate that our CD38 targeting ARM-enabled NK cells will kill CD38-positive multiple myeloma cells, and recruit other immune effector cells to assist in reducing the tumor burden."

Biohaven has initiated enrollment in the clinical trial and plans to enroll 25 patients for this single-center, open-label study (ClinicalTrials.gov Identifier: NCT04634435; https://clinicaltrials.gov/ct2/show/NCT04634435). The study will enroll newly diagnosed multiple myeloma patients who have minimal residual disease (MRD+) in first remission prior to an autologous stem cell transplant (ASCT).

David Spiegel M.D., PhD, inventor of the ARM technology and Professor of Chemistry and Pharmacology at Yale University, commented, "This is an important milestone in the development of the ARM therapeutic platform taking a novel technology from 'benchtop to bedside'. It also highlights Biohaven's commitment to benefit patients in need."

About ARMs: Antibody Recruiting Molecules

ARMs,antibody recruiting molecules, are engineered with modular components that are readily interchangeable, giving the platform tremendous flexibility and rapid development timelines. ARM compounds are being developed at Biohaven Labs to redirect a patient's own antibodies for therapeutic effect with multiple benefits over traditional monoclonal antibody therapies, including the potential for oral dosing. For BHV

1100, the ARM platform is being used to provide antigen targeting to NK cell-based therapies without genetic engineering. This NK cell targeting approach is also being investigated with allogeneic, or 'off-the-shelf', immune cell-based therapies.

About Multiple Myeloma Multiple myeloma is a type of blood cancer of the plasma cell that develops in the bone marrow, the soft tissue inside our bones. Healthy plasma cells produce antibodies, which are critical for the immune system's ability to recognize disease-causing entities, such as bacteria, viruses and tumor cells. In multiple myeloma, however, genetic abnormalities in a single plasma cell cause it to divide uncontrollably. This leads to the over-production of a single (monoclonal) antibody protein, referred to as an "M protein". Also, these cancerous cells divide to the point of crowding out normal, healthy cells that reside in the bone marrow. Many patients are diagnosed due to symptoms such as bone pain or fractures, kidney failure (thirst, dehydration, confusion), nerve pain, fever, and weakness. The American Cancer Society estimates that approximately 34,920 new cases will be diagnosed, and 12,410 deaths will occur in 2021 from multiple myeloma.

About BiohavenBiohaven is a commercial-stage biopharmaceutical company with a portfolio of innovative, best-in-class therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders and areas of unmet need. Biohaven's neuro-innovation portfolio includes FDA-approved NURTEC ODT (rimegepant) for the acute and preventive treatment of migraine and a broad pipeline of late-stage product candidates across three distinct mechanistic platforms: CGRP receptor antagonism for the acute and preventive treatment of migraine; glutamate modulation for obsessive-compulsive disorder, Alzheimer's disease, and spinocerebellar ataxia; and MPO inhibition for amyotrophic lateral sclerosis. More information about Biohaven is available atwww.biohavenpharma.com.

About PeptiDream PeptiDream Inc. is a public(Tokyo Stock Exchange 1st Section 4587) biopharmaceutical company founded in 2006 employing their proprietary Peptide Discovery Platform System (PDPS), a state-of-the-art highly versatile discovery platform which enables the production of highly diverse (trillions) non-standard peptide libraries with high efficiency, for the identification of highly potent and selective hit candidates, which then can be developed into peptide-based, small molecule-based, or peptide-drug-conjugate-based therapeutics. PeptiDream aspires to be a world leader in drug discovery and development to address unmet medical needs and improve the quality of life of patients worldwide. Further information regarding PeptiDream can be found at: http://www.peptidream.com.

Forward-looking Statement This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve substantial risks and uncertainties, including statements that are based on the current expectations and assumptions of Biohaven's management about BHV-1100 as a treatment for multiple myeloma. Forward-looking statements include those related to: Biohaven's ability to effectively develop and commercialize BHV-1100, delays or problems in the supply or manufacture of BHV-1100, complying with applicableU.S.regulatory requirements, the expected timing, commencement and outcomes of Biohaven's planned and ongoing clinical trials, the timing of planned interactions and filings with the FDA, the timing and outcome of expected regulatory filings, the potential commercialization of Biohaven's product candidates, the potential for Biohaven's product candidates to be firstin class or best in class therapies and the effectiveness and safety of Biohaven's product candidates. Various important factors could cause actual results or events to differ materially from those that may be expressed or implied by our forward-looking statements. Additional important factors to be considered in connection with forward-looking statements are described in the "Risk Factors" section of Biohaven's Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission onMarch 1, 2021, and Biohaven's subsequent filings with the Securities and Exchange Commission. The forward-looking statements are made as of this date and Biohaven does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

NURTEC and NURTEC ODT are registered trademarks of Biohaven Pharmaceutical Ireland DAC.Neuroinnovation is a trademark of Biohaven Pharmaceutical Holding Company Ltd.

ARM is a trademark of Kleo Pharmaceuticals, Inc.

Biohaven ContactDr. Vlad CoricChief Executive OfficerVlad.Coric@biohavenpharma.com

Media ContactMike BeyerSam Brown Inc.mikebeyer@sambrown.com312-961-2502

View original content to download multimedia:

SOURCE Biohaven Pharmaceutical Holding Company Ltd.

The above press release was provided courtesy of PRNewswire. The views, opinions and statements in the press release are not endorsed by Gray Media Group nor do they necessarily state or reflect those of Gray Media Group, Inc.

Read more:
Biohaven Enrolls Phase 1a/1b Clinical Trial of BHV-1100, Lead Asset from its ARM (Antibody Recruiting Molecule) Platform, in Combination with NK Cell...

Posted in Stem Cells | Comments Off on Biohaven Enrolls Phase 1a/1b Clinical Trial of BHV-1100, Lead Asset from its ARM (Antibody Recruiting Molecule) Platform, in Combination with NK Cell…

Curi Bio and NEXEL Announce Celogics, Joint Venture to Develop Leading iPSC-derived Cell Products – Business Wire

Posted: October 28, 2021 at 2:48 am

SEATTLE & SEOUL, South Korea--(BUSINESS WIRE)--Curi Bio, a global leader in development of human stem cell-based platforms for disease modeling and drug discovery, and NEXEL, a leader in induced pluripotent stem cell (iPSC) technology, today announced the formation of Celogics, a joint venture company focused on the development and commercialization of human iPSC-derived cell products for drug discovery, drug safety testing, and biological research. Celogics iPSC production and distribution headquarters will be located in Seattle, WA.

The US accounts for nearly 50% of the global stem cell market, and the Celogics joint venture partnership with market leader Curi Bio will represent a major strategic entry for Nexel into the US. Celogics will provide Nexels iPSC-derived cell products, including Cardiosight-S cardiomyocytes, to US and global markets, and will launch a Seattle-based iPSC production facility to support rapid growth and iPSC contract development and manufacturing services. Celogics will also develop and commercialize next-generation iPSC-derived cell products.

Curi Bio is a global leader in developing cardiac, skeletal muscle, and neuromuscular in vitro disease models, and provides market-leading products and services for modeling of human tissues for drug discovery. Curis 3D engineered tissue platform (Mantarray) can be used in combination with iPSC-derived cell models to develop advanced 3D heart and muscle tissue models for phenotypic screening. Curi Bio has previously been awarded more than $7M in grant funding by the US National Institutes of Health to support development of core technologies, including a proprietary approach for advanced functional maturation of iPSC-derived cardiomyocytes (ComboMat). By providing leading global pharmaceutical companies access to human-relevant models during preclinical drug development, Curi Bio helps leading pharmaceutical companies develop safer and more effective therapeutics in less time, at lower cost. NEXEL was the first Korean company to in-license iPSC technology and has advanced the in vitro toxicity field through successful commercialization of iPSC-derived cells that better mimic human cellular function.

Human iPSC-derived cells are rapidly becoming a vital tool in the drug development industry for the discovery, preclinical efficacy testing, and safety profiling of new medicines. iPSCs can be differentiated into a wide variety of human cell types, including cardiomyocytes, neurons, hepatocytes, and many others, and can be created from healthy individuals or patients who have specific diseases through a process called cellular reprogramming. iPSC-derived disease models serve as platforms for discovery of next-generation therapeutics.

Researchers in the pharmaceutical industry are increasingly relying on gene editing technologies such as CRISPR to create genetically-engineered iPSC-derived cellular models of human diseases, including cardiomyopathies and muscular dystrophies. Following major collaborative initiatives between US regulatory agencies and companies in the iPSC industry, human iPSC-derived cardiomyocytes are increasingly being used by leading global pharmaceutical companies in cardiac safety screening.

As a joint venture partnership between Curi Bio and Nexel, Celogics will be extremely well-positioned to meet the large and rapidly growing market need for high-quality human iPSC-derived cell products, said Curi Bio CEO Michael Cho. We look forward to helping cutting-edge researchers and pharmaceutical companies accelerate the discovery and development of next-generation therapies."

"Celogics is leading the global market with stem cell-derived somatic cell products for toxicity evaluation and drug discovery, said Nexel CEO Choong-seong Han. We are committed to developing and producing exceptional iPSCs that pharmaceutical quality control standards demand.

About Curi Bio

Curi Bios preclinical discovery platform combines human stem cells, systems, and data to accelerate the discovery of new medicines. The Curi Engine is a seamless, bioengineered platform that integrates human iPSC-derived cell models, tissue-specific biosystems, and AI/ML-enabled phenotypic screening data. Curis suite of human stem cell-based products and services enable scientists to build more mature and predictive human iPSC-derived tissueswith a focus on cardiac, musculoskeletal, and neuromuscular modelsfor the discovery, safety testing, and efficacy testing of new drugs in development. By offering drug developers an integrated preclinical platform comprising highly predictive human stem cell models to generate clinically-relevant data, Curi is closing the gap between preclinical data and human results, accelerating the discovery and development of safer, more effective medicines.

For more information, please visit http://www.curibio.com.

About NEXEL

NEXEL, Co., Ltd. is a bio-company that was incorporated in 2012 with proprietary stem cell technologies. Their philosophy is to make a better place by supporting innovative research around the globe by providing high quality stem cell-derived cell products. NEXEL, Co., Ltd. launched the Cardiosight-S in 2018 which has since been validated on multiple platforms as a pure and functional population of hiPSC-derived cardiomyocytes. Other product lines include the Hepatosight-S (iPS-derived hepatocytes) and the Neurosight-S (iPS-derived neurons).

For more information, please visit: http://www.nexel.co.kr

See more here:
Curi Bio and NEXEL Announce Celogics, Joint Venture to Develop Leading iPSC-derived Cell Products - Business Wire

Posted in Stem Cells | Comments Off on Curi Bio and NEXEL Announce Celogics, Joint Venture to Develop Leading iPSC-derived Cell Products – Business Wire

What Are the Benefits of Turmeric and Can It Be Used to Prevent or Treat Cancer? Here’s What the Science Says – On Cancer – Memorial Sloan Kettering

Posted: October 28, 2021 at 2:47 am

You may have read about the health benefits of turmeric, a spice native to southeast Asia. For more than 5,000 years, people have used it to treat a variety of ailments, such as skin disorders and digestive issues. Research suggests that its active ingredient, curcumin, may even help prevent or treat cancer. So should you ramp up your intake?

Jason Hou

Memorial Sloan Kettering Cancer Center Integrative Medicine pharmacist Jason Hou says you can go ahead and add turmeric to your favorite foods. Dr. Hou manages MSKs About Herbs database, a hub of information on herbs and supplements as they relate to cancer care. But before you stock up on turmeric capsules or vitamins, talk to your MSK healthcare provider, especially if youre in active treatment.

Just because a product is labeled as natural does not always mean its safe especially for people with cancer, Dr. Hou says.

Heres what else Dr. Hou wants you to know about turmeric.

Turmeric reduces inflammation, which is at the root of many diseases, including cancer. Animal and lab studies show that turmeric can help prevent cancer growth and kill certain cancer cells, but we dont know if it has the same effect in humans. We need large clinical trials to figure that out, says Dr. Hou. The research community is on it. Dr. Hou cites a phase 2 study that combined curcumin and conventional chemotherapy to treat people with advanced colorectal cancer. The researchers found that curcumin is safe and tolerable in these patients, and when combined with conventional chemotherapy, has the potential to improve overall survival (how long someone lives after starting treatment) and progression-free survival how long someone is on treatment before cancer progresses. Other studies are ongoing.

Small studies among people with cancer show that turmeric can help improve quality of life. In one study, people who used a turmeric-based topical cream had reduced skin irritation caused by chemotherapy. In another, a mouthwash containing curcumin reduced mouth swelling. Turmeric can also help lower pain in some breast cancer patients with joint problems. This is encouraging, Dr. Hou says, adding that similar trials are underway in people with prostate, colorectal, and pancreatic cancer.

In fact, MSK is recruiting cancer survivors with pain in their muscles, bones, and joints for a study of a patch that contains turmeric. If youre interested in learning more, call 646-888-0844.

MSKs Integrative Medicine Service offers turmeric and curcumin supplements through its herbal dispensary program, located at MSKs Breast and Imaging Center. Patients must be referred to the dispensary after being assessed by an MSK Integrative Medicine physician or advanced practice provider.

Theres no evidence turmeric as a spice is harmful, Dr. Hou says. But for anything more than that, you should consult your healthcare provider or an Integrative Medicine specialist at MSK. Thats because consuming higher amounts of curcumin found in turmeric capsules, for example may interfere with certain chemotherapies, making them less effective. Turmeric can also increase the risks of bleeding and kidney stones, and too much can give you a stomachache.

If youd like to learn more about how turmeric may fit into your cancer care plan, you can book a consultation with a member of MSKs Integrative Medicine Service. Call 646-888-0845 for more information.

Key Takeaways

View post:
What Are the Benefits of Turmeric and Can It Be Used to Prevent or Treat Cancer? Here's What the Science Says - On Cancer - Memorial Sloan Kettering

Posted in Integrative Medicine | Comments Off on What Are the Benefits of Turmeric and Can It Be Used to Prevent or Treat Cancer? Here’s What the Science Says – On Cancer – Memorial Sloan Kettering

Getting to Know Kate Roth at Beacon Integrative Medical Center in Rexburg – East Idaho News

Posted: October 28, 2021 at 2:47 am

EastIdahoNews.com is highlighting hardworking people who make our local businesses a success. Every Sunday, were Getting to Know YOU!

1. Name, job title and company: Kate Roth MSN, ARNP, FNP-C, WHNP-BCP, ARBHRT-C Nurse Practitioner and Medical Director for Beacon Specialty and Family Practice

2. What does your company do and what are your responsibilities? We provide an array of family medicine services. I specialize in comprehensive womens healthcare and bio-identical hormone replacement therapy. She treats thyroid disease, polycystic ovarian syndrome, infertility and vaginal rejuvenation treatment. I also perform annual wellness examinations, family planning, treatment of migraine headache, pre-marital exams and bio-identical hormone pellet insertion for men and women. My responsibilities as medical director include maintaining compliance with regulatory state board regulations, HIPAA security services, staff training and competency evaluation in accordance with state and federal law.

3. Where were you born and when is your birthday (dont need to include year)? Champaign, Illinois, October 2

4. How long have you lived in eastern Idaho and what city do you live in now? Ive lived in eastern Idaho for 18 years. (Didnt want to say the city she lives in).

5. Tell us about your first job after high school/college. Hired as staff, then charge RN for the University of Illinois at Chicagos first bone, or stem cell, transplant center.

6. What is the best business decision youve ever made? Partnering with Beacon Integrative Medical Center.

7. Tell us about your family. Wonderful husband, three children all active in sports and school activities. We enjoy doing anonymous service projects, hiking, watching movies, reading books, traveling, and skiing together.

8. Tell us about a movie or book that has inspired you the most in life. (Didnt want to answer)

9. Tell us about a lesson you learned from a mistake you made in your career/business. Corporate healthcare is not for me. I believe in providing compassionate, comprehensive healthcare and making sure my patients feel heard.

10. What is a goal you hope to accomplish in the next 12 months? Grow personally, physically, spiritually and professionally. Always learning!

11. What is one piece of advice you have for someone who wants to do what youre doing? Listen to and love your patients.

12. If you could do it all over again, what would you do differently? Nothing at all. I am thrilled to be who and where I am today.

13. Where is your favorite place to eat in eastern Idaho? Home!

14. Tell us something surprising about yourself. (Didnt want to answer)

15. How do you like your potatoes? Roasted with garden-fresh herbs.

If you have an employee or co-worker who we should get to know, email rett@eastidahonews.com.

Originally posted here:
Getting to Know Kate Roth at Beacon Integrative Medical Center in Rexburg - East Idaho News

Posted in Integrative Medicine | Comments Off on Getting to Know Kate Roth at Beacon Integrative Medical Center in Rexburg – East Idaho News

The Final Verdict on Drinking Tea for Weight Loss Eat This Not That – Eat This, Not That

Posted: October 28, 2021 at 2:47 am

I think we can all agree that it would be nice to have a miracle drink for weight loss, one where we could just take a few sips and instantly shed the pounds.

But sadly, this doesn't exist. And even though there isn't a miracle weight loss beverage for us to enjoy, there are types of drinks that can help support our goals as we pursue a healthy lifestyle.

Tea is one of the most talked-about of these "weight loss drinks," so we decided to learn as much as we can about why it's so highly talked about among those wanting to lose weight.

To do this, we spoke to Lauren Manaker, MS, RDN, author of The First Time Mom's Pregnancy Cookbook and Fueling Male Fertility and member of the Eat This, Not That! Medical Expert Board, and her response? That she supports using tea for weight loss as long as it's coupled with a healthy diet.

Read on to learn more about what Manaker has to say on how tea can help you lose weight, and for more healthy eating tips, make sure to sign up for our newsletter to get daily recipes and food news in your inbox!

The natural ingredients found in certain teas can make them great for supporting weight loss and weight management. For example, according to Manaker, "green tea contains catechins, which are antioxidants that have been linked to fat loss and an increased metabolism."

There are different types of catechins found in green tea, and one of the most predominant is known as EGCG. Many researchers attribute most of green tea's health benefits to its high quantity of catechins like EGCG.

Catechins in green tea have been known to support weight loss in a multitude of ways, including shrinking fat cells, blocking the formation of new fat cells, and regulating blood sugar.

RELATED: 11 Healthiest Drinks for Weight Loss

According to Manaker, "other teas, like black and oolong, have been shown to support weight loss too." There hasn't been as much research done on these types of tea as there has been for green tea, but current data shows they can still be helpful for your goals.

A study from the Chinese Journal of Integrative Medicine discovered that obese and overweight participants who consumed a daily serving of oolong tea for six weeks saw a decrease in body fat. Part of oolong's health benefits could be attributed to its catechin content as well, but green tea still contains the highest amount.

A recent study published in the European Journal of Nutrition found surprising results related to black tea and its potential weight loss benefits as well.

Researchers in this study learned that black tea might actually be able to alter the bacteria in your gut, which can attribute to weight loss. However, this study was performed on mice, so more research still needs to be done.

RELATED: 5 Best Metabolism-Boosting Teas for Weight Loss

Teas like green, oolong, and black can be great for supporting your weight loss goals, but Manaker reminds us that how you drink your tea makes a huge difference.

"If the tea is replacing caloric drinks like regular sodas, any variety would likely be a good choice when supporting weight loss," says Manaker, "and as long as the tea isn't being enjoyed with a large amount of sugar, honey, cream, or other caloric additions, it can be a fantastic choice for weight loss support as well as overall health support."

So when reaching for a cup of tea to help you with your weight loss goals, just remember that although it can help you, it's your daily food, movement, and sleep choices that make all the difference.

For more healthy eating news, make sure to sign up for our newsletter!

Read these next:

See original here:
The Final Verdict on Drinking Tea for Weight Loss Eat This Not That - Eat This, Not That

Posted in Integrative Medicine | Comments Off on The Final Verdict on Drinking Tea for Weight Loss Eat This Not That – Eat This, Not That

We asked a family practitioner, gynecologist and physical therapist what they wish patients knew – WRAL.com

Posted: October 28, 2021 at 2:47 am

By Crissy Fishbane, WRAL contributor

Going to the doctor can be intimidating.

I am guilty of putting off certain doctors appointments for years. Yes, you read that right. Not months, but years.

Of course, I am busy, as all moms are. Most moms I know spend entire afternoons carting their kiddos around to appointments and practices all over town, their own health and well-being often taking a backseat.

But we cant ignore the fact that going to the doctors office can be scary. We tend to put doctors on a pedestal and often feel overwhelmed as we head in for our 10 precious minutes of solo time with our healthcare provider (to ask a years worth of questions).

I often find myself wondering what the doctor is thinking as they poke and prod my body (which is rapidly approaching middle-age. Shh, dont tell!). Are they judging my weight gain? Do they shudder at the sight of my bunion or shake their head when they come across that regretful tattoo I got back in college?

I thought it would be helpful to ask a few doctors what it is they wish their patients knew. In my quest for insights I spoke with a medical doctor, gynecologist, and physical therapist. Heres what they had to say:

First, I spoke with Elizabeth Sierakowski, MD, DABFM, DABOIM. Sierakowski is the medical director & provider at the Raleigh & Holly Springs locations of Essential Health. She is triple trained in family medicine, integrative medicine and functional medicine and has practiced from coast to coast.

Heres what Dr. Sierakowski had to say:

Your relationship with your provider can be so much better. With any professional advisor:

1. Seek the right fit, and be clear about your goals. "Non-compliance" is when your goals and the doctor's goals for you don't align. You can always seek another opinion or another relationship. Many practices dont offer free Meet and Greet appointments, but you can always ask! Increasingly providers are on media, or have a video of them talking on their clinics website. That can help you get a feel for someone ahead of time.

2. Once you find your fit, stick with it for a reasonable amount of time. Too many cooks spoil the soup. Medicine is absolutely a blend of art and science. While some treatment plans are very cut and dry and you may get the same answer from several people, most have significant room for variability. Adding layers of opinion, herb, prescription, oils, & other treatments can make you sicker instead of better or at best can hinder progress.

3. Prepare for your appointments. Call ahead and make sure you state what your chief goal is. Like your hair appointments, if you're coming in for a quick cut and are expecting foils, it won't end well.

4. Navigate the conversation. Ask up front for: Listening (is this bad?), Advice (what can I do?), or Intervention (is there a treatment?). Sometimes your doctor will suggest more than what you've asked for, but that's our job, too.

5. Be Honest. If you feel you cant tell your provider about your supplement regimen, barriers to change, home environment, fears, or anything else critical to creating an appropriate treatment plan for you thats a big sign thats not the right relationship for you.

6. Give feedback! Both positive and negative. Your providers only ever get better if you can tell them when you've improved, or if something isn't working, or especially if you've found healing from someone else. Learning from the approach of my colleagues is critical to being able to help that many more people.

Sierakowski also said, As you seek a provider who treats you with humanity and respect, please remember we are human beings, too, doing the very best we can to alleviate suffering in the world.

Next up, I thought it would be interesting to hear from a physical therapist, so I spoke to Holly Durney, PT, OCS. Durney is an APTA Orthopedic Certified Specialist and has pelvic floor rehabilitation training from the Herman and Wallace Pelvic Rehabilitation Institute. She utilizes her knowledge of orthopedics to treat pelvic pain, pre- and postnatal issues and incontinence at Smart Athlete Physiotherapy.

Heres what Dr. Durney had to say:

I wish my patients knew that pregnancy and delivery can be treated as an orthopedic injury. Unlike ankle sprains and low back pain that typically get referred out for care, pregnancy is something that women are expected to be able to rehabilitate on their own unless there's a traumatic delivery or some sort of complication. But if you think about the postural changes, the ligament changes, the structural changes and the muscle damage that occurs during pregnancy and delivery, standard outpatient care is something that should be sought regardless of trauma or complication during delivery. My hope is to encourage women to seek care postpartum as a standard part of their postnatal care. I hope to encourage women to seek physical therapists advice in order to reactivate their muscles and reclaim their body after giving birth.

Finally, I decided to take it to the most intimate of doctor-patient relationships. Who doesnt wonder what their gynecologist would secretly love to tell their patients? So, I spoke to Polly Watson, MD FACOG NCMP, founder and owner of Hormone Wellness MD.

Heres what Dr. Watson had to say:

I wish you knew and could take to heart that self care isn't selfish. So many women wait far too long to seek medical care. And they've been suffering for years before they finally take some time for themselves. The best diet and lifestyle advice, the most complicated cutting edge test, the most advanced nutraceutical protocol, none of that can be optimally helpful with a patient that isn't able to set boundaries for self care at work and at home.

So I invite you to create some space for yourself to step forward. Look at your calendar, and find one thing that you can say no to or you can delegate. If you could claim back 30 minutes a day to take care of yourself imagine how your health would change. The world is a pretty stressful place, especially now. Your body and your mind deserve some rest that's restorative. So let's reimagine what's possible for women's health and start by stepping forward and creating some space for yourself and your own self care.

To open up more time for self-care, Dr. Watson suggested things like taking a break from social media, letting up on the Netflix habit or ordering groceries electronically and having them delivered rather than spending time at the grocery store.

She also suggested trying journaling as a time of personal reflection. To work on lowering cortisol Dr. Watson suggests exploring tapping, meditation, or visualization. She also stressed the importance of social connection and spending time connecting with a treasured friend.

What do all of the doctors suggestions have in common?

All the doctors expressed genuine compassion for their patients. It is vital to build a relationship with a trusted provider and to be honest with them in your communication. If you dont have that kind of relationship it may be time to seek out a new provider.

Of course, it goes without saying, doctors are human and are certainly not infallible. Its crucial that women learn to trust their body and follow their intuition. If something doesnt feel right and a doctor is not listening to your concerns it is worth pursuing a second opinion. There are plenty of good doctors out there who are willing to listen and want to help you find health.

Crissy Fishbane is the co-founder of HER Health Collective, a supportive community and resource hub for moms. She is a certified therapeutic exercise specialist, personal trainer, wellness coach, and former high-school psychology teacher. Crissy believes in a holistic approach to womens health and is a strong advocate of improved screening and treatment of perinatal mood disorders. She is passionate about building a supportive community for moms where they can make genuine connections and build authentic relationships.

Read the rest here:
We asked a family practitioner, gynecologist and physical therapist what they wish patients knew - WRAL.com

Posted in Integrative Medicine | Comments Off on We asked a family practitioner, gynecologist and physical therapist what they wish patients knew – WRAL.com

Design and integrative therapy combine in Laura Deschl’s garments – Dezeen

Posted: October 28, 2021 at 2:47 am

Design Academy Eindhoven graduate Laura Deschl has developed The Healing Imprint, a therapeutic garment that looks like activewear but is made to help heal trauma.

The project was developed to explore the potential of combining acupressure a non-invasive practice originating in traditional Chinese medicine with yoga-like movement to treat psychological trauma.

Deschl produced custom-knit garments with a grid stitched into them that allows small massage balls to be inserted and moved onto specific acupressure points on the body, feet, hands and head.

The garments' aesthetic is similar to activewear or leisurewear, and a full set includes a bodysuit, gloves, socks and a pillow.

The idea is to combine acupressure with an embodied movement practice based on yoga, which would allow a person's bodyweight to heighten the pressure at the targeted "acu-points."

Deschl based The Healing Imprint on research that shows how physical therapies can be incorporated into psychotherapy to help people heal from psychological trauma, in an approach known as integrative therapy.

She was particularly inspired by the work of Bessel van der Kolk, whose 2014 book The Body Keeps the Score documents the effects of trauma and an array of methods that can be used to treat it.

"I was inspired by how he is incorporating 'untypical' ways of healing trauma, such as through yoga, tapping and community," Deschl told Dezeen.

"My research also encompassed certain other thinkers, but their take on healing trauma through the body is somehow similar," she continued. "One thing is certain: they are all convinced that the body needs to play a major role in overcoming the imprint left on the body caused by a traumatic event."

Acupressure has been used to address symptoms of post-traumatic stress disorder, as well as trauma-related anxiety and depression.

With The Healing Imprint garments, the acupressure aims to help the wearer access buried memories or emotions, while the trauma-sensitive yoga practice would facilitate introspection around those recollections.

Deschl said that a person's body and their emotions are "two elements that are crucial for one's sense of self, but are often highly impaired as a result of trauma".

"Many people with histories of trauma and neglect experience an extreme disconnection from their body due to a deep divide between the sense of self and sensory experiences," said Deschl.

"The goal of this project is to help patients train embodiment and thus bring them closer to their bodies."

One of The Healing Imprint garment sets is knitted from predominantly merino wool plated with an elastic yarn, which was produced specifically for the project.

A second set with meridian patterns is made from a recycled knitted athleisure fabric, while the massage balls are gemstones.

The Healing Imprint includes a set of illustrations showing where to place the balls for which symptoms, and Deschl worked with a psycho-motor therapist to facilitate test sessions with trauma patients.

Deschl tested the garments at Eindhoven mental health institute GGzE and is seeking funding to further develop the project.

A social designer and artistic researcher, Deschl has a background in fashion and textiles as well as yoga teaching.

The Healing Imprint is her graduate project from the Master of Fine Arts and Design at Design Academy Eindhoven and is emblematic of her interdisciplinary approach.

"The garment is not only an interface for an individual to access embodied knowledge and self-awareness, but also represents how design can converge fields such as science, business, medicine, psychiatry and textile-making," said Deschl.

Other designers to have made tools for therapy include Ariadna Sala Nadal, whose Balisa kit is meant to help children express their emotions, and Nicolette Bodewes, whose tactile objects are to assist adults in talk therapy.

Photography is by Iris Rijskamp.

See the article here:
Design and integrative therapy combine in Laura Deschl's garments - Dezeen

Posted in Integrative Medicine | Comments Off on Design and integrative therapy combine in Laura Deschl’s garments – Dezeen

Ethan Nadelmann: How To End the Drug War (and What Comes Next) – Reason

Posted: October 28, 2021 at 2:47 am

As anyone who is involved in drug policy can tell you, Afghanistan wasn't really America's longest war. That shady honor belongs to the war on drugs, which has been waged at the state, local, and federal levels for well over a century, even before President Richard Nixon officially declared in 1971 that he was starting "an all-out offensive" on the "drug abuse" he called "America's public enemy number one."

Yet it's obvious that the drug war is in fact winding down. In the 1990s, medical marijuana was legalized in various states. Now 16 states have legalized recreational marijuana, with more to come. Last fall, nine out of nine drug legalization or decriminalization measures passed at the ballot box, the use of MDMA to treat PTSD is in final clinical trials with the Food and Drug Administration, and there is an increasingly visible cultural shift that is welcoming to psychedelics and other mind-expanding substances. This November, LSD even comes to that safest of all cultural playgrounds, Broadway, with the musical Flying Over Sunset, a fictional account of a meeting between novelist Aldous Huxley, playwright/ambassador Clare Boothe Luce, and movie star Cary Grant, all of whom experimented with psychedelics in the late 1950s and early '60s.

Nick Gillespie's guest is the one person in the best position to explain and interpret the country's shifting attitudes toward drug prohibition and drug use. He's Ethan Nadelmann, the 64-year-old founder and former head of the Drug Policy Alliance, one of the oldest and most effective outfits fighting for pharmacological freedom. A former college professor who taught political science, Nadelmann brings together an academic's rigor and depth of knowledge with an activist's sense of urgency and energy (read a 1994 Reason interview with him conducted by Jacob Sullum).

Over the years, Nadelmann has allied and sparred with everyone across the political spectrum to make drug policy more humane and less punitive while also talking up the positives of responsible drug use. You can listen to him on his new weekly podcast Psychoactive, where recent guests have included psychedelic enthusiast and best-selling author Tim Ferriss, leading psychotherapist and psychopharmacologist Julie Holland, integrative medicine guru Andrew Weil, and advice columnist Dan Savage on "sex, drugs, and freedom."

This is a great and rollicking conversation about the past 50 years of drug laws and drug cultureand what comes next as America oh-so-slowly starts pulling out of its longest war.

Photo: Gage Skidmore.

Read the original:
Ethan Nadelmann: How To End the Drug War (and What Comes Next) - Reason

Posted in Integrative Medicine | Comments Off on Ethan Nadelmann: How To End the Drug War (and What Comes Next) – Reason

Page 610«..1020..609610611612..620630..»